Healthcare Industry News: Magnetic Resonance Imaging
News Release - July 6, 2009
Covidien Announces Health Canada Approval for its Generic Myocardial Perfusion Imaging KitST. LOUIS--(HSMN NewsFeed)--Covidien (NYSE: COV ), a leading global provider of healthcare products, today announced that Health Canada has approved the Company’s Abbreviated New Drug Submission (ANDS) for its Kit for the Preparation of Technetium Tc 99m Sestamibi Injection. Covidien’s generic product is fully substitutable for Cardiolite(R), a myocardial perfusion imaging agent used for detecting coronary artery disease.
With Health Canada approval of the ANDS, which was filed by the Company’s Canadian subsidiary, Covidien’s generic product is expected to be available for customers in Canada this summer. The Company’s generic product also is available in the U.S., the U.K., Denmark, Germany and Puerto Rico.
“We are pleased to receive approval in Canada and to introduce this generic diagnostic option to meet patients’ needs,” said Timothy R. Wright, President, Pharmaceutical Products and Imaging Solutions, Covidien.
Covidien’s Imaging Solutions business is a leading provider of radiopharmaceuticals used in nuclear medicine imaging procedures. It also supplies contrast media delivery systems, which combine contrast media and power injectors, for Computed Tomography (CT), X-ray and Magnetic Resonance Imaging (MRI) procedures.
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2008 revenue of nearly $10 billion, Covidien has more than 41,000 employees worldwide in 59 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.
Cardiolite(R) is a trademark of Lantheus Medical Imaging, Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.